This federal contract Indefinite Delivery Vehicle (IDV) is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Incyte Corporation, a global biopharmaceutical company. The BPA, valued at $3,750,000, is for the supply of Pemazyre (pemigatinib), Incyte's specialized oncology drug used to treat certain types of cancer. The BPA, which runs through November 20, 2025, is issued under Incyte's Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs, valued at $541 million.
Under this BPA, Incyte will fulfill delivery orders for Pemazyre tablets in 4.5mg, 9mg, and 13.5mg dosages to VA medical centers and facilities across the United States. A sample $12,725.23 task order was awarded to Incyte by the VA's Veterans Integrated Service Network 22 for the delivery of Pemazyre tablets to support healthcare services for veterans within VISN 22's coverage area. All contract awards have been issued as firm fixed price with no set-aside designations, indicating Incyte competes in the unrestricted federal marketplace for these critical pharmaceutical supply contracts.
Generated 12/10/24, 2:13 PM